Core Viewpoint - Fosun International (00656) issued a profit warning, projecting a loss of approximately RMB 21.5 billion to RMB 23.5 billion for the fiscal year 2025, primarily due to one-time non-cash impairment charges and value reassessments, which do not affect the company's overall operations and cash flow [1][2] Group 1: Financial Performance - The projected loss for fiscal year 2025 is attributed to significant asset impairment provisions in the real estate sector, which is under pressure due to a prolonged downturn and weak market demand [1] - The company plans to dynamically adjust its operational and sales strategies based on market conditions, aiming to enhance marketing efforts and accelerate cash recovery [1] - In the insurance sector, Fosun's Portuguese insurance reported a net profit of €170 million for the first three quarters of 2025, a year-on-year increase of 11.7% [3] - Fosun's health insurance business revenue reached RMB 7.84 billion, a 50% year-on-year growth, while net profit for the year was RMB 130 million [3] Group 2: Strategic Focus - Fosun emphasizes its commitment to a "focus on core business" strategy and a "streamlining" financial strategy to promote business growth and solidify long-term value [1][3] - The company has engaged in significant partnerships in the innovative drug sector, including a global exclusive licensing agreement with Pfizer worth over $2 billion and a strategic collaboration with Clavis Bio potentially worth up to $7.25 billion [2] - Fosun's tourism segment has also shown strong performance, with Club Med's resorts achieving a 90% average occupancy rate during the Spring Festival holiday [3] Group 3: Market Confidence - Fosun has increased its share buyback efforts to signal confidence in its long-term development prospects, planning to repurchase shares up to HKD 1 billion following the 2025 annual performance announcement [4] - The company previously repurchased shares worth HKD 48.24 million, acquiring 13.02 million shares [4]

Core Viewpoint - Fosun International (00656.HK) issued a profit warning, projecting a loss of approximately RMB 21.5 billion to RMB 23.5 billion for the fiscal year 2025, primarily due to one-time non-cash impairment charges and value reassessments, which do not affect overall operations and cash flow [1][5][6]. Group 1: Financial Performance and Strategy - The significant loss is attributed to the ongoing downturn in the real estate sector, leading to a soft market demand and pressure on the group's real estate business, prompting substantial asset impairment provisions [6][8]. - The company emphasizes its commitment to a "focus on core business" strategy and a "streamlining" financial strategy to promote business growth and solidify long-term value [1][5]. - Analysts noted that the non-cash adjustments to asset and goodwill values under Hong Kong accounting standards do not impact cash flow, reinforcing the company's stable fundamentals [2][6]. Group 2: Core Business Performance - In the pharmaceutical sector, Fosun's innovative drugs have opened significant global market opportunities, including a global exclusive licensing agreement with Pfizer worth over $2 billion and a strategic partnership with Clavis Bio potentially yielding up to $7.25 billion [7]. - The insurance segment showed strong performance, with Fosun Portugal Insurance reporting a net profit of €170 million, a year-on-year increase of 11.7%, and domestic insurance companies also reported substantial growth in premiums and net profits [3][7]. - In the tourism sector, Fosun's Club Med resorts achieved an average occupancy rate of 90% during the Spring Festival, and Atlantis Sanya recorded a total revenue of over RMB 124 million during the holiday, marking a 20% year-on-year increase [3][7]. Group 3: Market Confidence and Future Outlook - Fosun has increased its share buyback efforts to signal confidence in its long-term development prospects, planning to repurchase shares up to HKD 1 billion following the 2025 annual results announcement [4][8]. - The proactive decision to recognize substantial non-cash losses is seen as a strategy to clear risks and focus resources on core businesses such as pharmaceuticals, insurance, and tourism, enhancing future growth potential [8].

Core Viewpoint - Fosun International (00656.HK) anticipates a significant loss of approximately RMB 21.5 billion to RMB 23.5 billion for the fiscal year ending December 31, 2025, compared to a loss of around RMB 4.35 billion in 2024, primarily due to asset impairment and revaluation adjustments [1] Group 1: Financial Performance - The projected loss for the fiscal year 2025 is attributed to a substantial non-cash impairment charge and revaluation of certain assets [1] - The real estate sector continues to face a downturn, leading to weak overall market demand, which has put pressure on the company's real estate business [1] Group 2: Strategic Adjustments - The company has made significant impairment provisions for real estate projects showing signs of impairment, adhering to a principle of financial prudence [1] - Fosun International plans to dynamically adjust its operational and sales strategies based on market conditions, aiming to enhance marketing efforts and accelerate capital recovery [1] Group 3: Non-Core Business Impact - Due to market changes, the company has also recognized impairment provisions for goodwill and intangible assets in certain non-core business segments to reflect their objective value [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公 告 乃復 星 國際 有限 公 司（「 本公司 」， 連同 其 附屬 公 司 統稱 「本集團 」） 董事 會（「董事會 」）根 據香 港 聯合 交 易所 有 限公 司 證券 上市 規 則（「 上市規 則 」）第 13.09(2)(a)條及《 證 券及 期 貨 條例 》（香 港 法例 第 571 章 ）第 XIVA 部項 下 之內 幕 消息 條文 而 刊發 。 董事會謹此通知本公司之 股 東 及 潛 在 投 資 者 ， 根 據 本 公 司 現有資料及截至 2025 年 12 月 31 日 止年 度（「2025 財 政 年 度 」）之最 新 未經 審核 綜 合管 理 賬 目， 2025 財 政年 度 本公 司 歸屬 於 母公 司股 東 之虧 損 預計 約為 人 民幣 215 億 元至人民幣 235 億 元（2024：約 人 民 幣 43.5 億 元虧 損）。本公 司 依據 財 務審 慎性原則，對部分資產 ...

Core Viewpoint - Fosun International plans to invest 105 million yuan in Zhejiang Shangmeng Technology Co., Ltd. to acquire a 51.0879% stake, making it the largest shareholder, which will enhance the company's capital and operational capabilities in the payment industry [3][4]. Group 1: Investment Details - Fosun International will increase Shangmeng Technology's registered capital from 100.5 million yuan to 205.5 million yuan through this cash investment [3]. - The investment is aimed at strengthening Shangmeng Technology's capital base to meet regulatory requirements and support its licensed operations [4]. Group 2: Strategic Implications - The acquisition is expected to integrate Shangmeng Payment's capabilities with Fosun's extensive membership system and consumer ecosystem, potentially reducing third-party payment costs and increasing customer loyalty [6]. - The investment also addresses regulatory requirements, as the minimum registered capital for payment institutions operating certain services is set at 205 million yuan [4]. Group 3: Market Context - Shangmeng Technology, established in August 2009, is the wholly-owned parent company of Shangmeng Payment, which holds a payment business license valid until December 2026 [3]. - Recent scrutiny of Shangmeng Payment due to high-interest scenarios has raised concerns, but the company has denied any operational halts while committing to compliance checks [6]. Group 4: Future Outlook - The capital infusion is expected to provide a solid foundation for rapid business development and technological advancement for Shangmeng Technology [7]. - Analysts suggest that Shangmeng Technology should focus on real consumption scenarios and strict transaction controls to ensure compliance before expanding its business scale [6].

Core Viewpoint - Fosun International plans to invest 105 million RMB in Shangmeng Technology, acquiring a 51.0879% stake and becoming the largest shareholder, which will increase Shangmeng Technology's registered capital from 100.5 million RMB to 205.5 million RMB [3][4] Group 1: Investment Details - The investment will directly inject capital into Shangmeng Technology rather than paying existing shareholders, which is a unique approach in the payment industry [4] - The capital injection aims to strengthen Shangmeng Technology's capital base to support its licensed operations and meet regulatory requirements [4] - The minimum registered capital requirement for Shangmeng Payment, a subsidiary of Shangmeng Technology, is calculated to be 205 million RMB based on regulatory guidelines [4] Group 2: Strategic Implications - The acquisition of the payment license is expected to integrate Shangmeng Payment's capabilities with Fosun Group's extensive member system and consumption ecosystem, potentially reducing third-party payment costs and enhancing customer loyalty [5] - There are concerns regarding Shangmeng Payment's past issues with regulatory scrutiny, which necessitate a thorough review of existing high-risk merchants and non-compliant businesses [5][6] - The collaboration between Fosun International and Shangmeng Technology is seen as a way to leverage payment licenses for financial transactions within Fosun's ecosystem while ensuring compliance [5][6] Group 3: Future Outlook - Analysts suggest that Shangmeng Technology should focus on real consumption scenarios and strictly control merchant access to avoid high-risk and non-compliant activities [6] - The capital reserve from this investment is expected to provide robust support for Shangmeng Technology's rapid business development and technological capabilities [6]

II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00656 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 8,166,663,124 | | 0 | | 8,166,663,124 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 8,166,663,124 | | 0 | | 8,166,663,124 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年2月28日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 復星國際有限公司 | | | 呈交日期: ...

Group 1 - The core viewpoint of the announcement is that Fosun International plans to repurchase shares worth up to HKD 1 billion due to the belief that the current stock price does not reflect the company's long-term value [1] - The repurchase plan is seen as a demonstration of Fosun's confidence in its future development, particularly in light of recent commercialization of innovations and deepening global operations [1][2] - Analysts note that Fosun's core business segments, including biomedicine, cultural tourism, and insurance, have shown strong momentum since the beginning of 2026 [2] Group 2 - In the biomedicine sector, Fosun's innovative drug platform has made significant strides, including a deal with Eisai Co., Ltd. for a potential total of over USD 300 million in Japan, the fourth largest pharmaceutical market globally [2] - The company has also signed a global exclusive licensing agreement with Pfizer, potentially worth over USD 2 billion, and a strategic cooperation with Clavis Bio that could yield up to USD 7.25 billion in payments [2] - In the cultural tourism sector, Fosun's various product lines have performed well, with significant increases in visitor numbers and revenue during the Spring Festival period [2] Group 3 - In the insurance sector, Fosun's two domestic insurance companies reported substantial growth in premium income and net profit for 2025, with Fosun United Health Insurance achieving a revenue of HKD 7.84 billion, a 50% increase year-on-year [3] - Fosun's life insurance subsidiary, Fosun Baodexin, reported an insurance business income of HKD 12.598 billion, a 36.17% increase, and a net profit of HKD 647 million, reflecting a significant growth of over 450% year-on-year [3] - The robust growth in core businesses is considered a key catalyst for the share repurchase, as the company aims to improve its asset structure and market valuation [3][4]

Core Viewpoint - Fosun International (00656.HK) announced a share buyback plan with a total amount not exceeding HKD 1 billion, citing that the current stock price does not reflect the company's long-term value and expressing confidence in its future development [1] Group 1: Buyback Announcement - The company plans to conduct share buybacks from the release of its 2025 annual results until the 2026 annual general meeting [1] - The buyback is intended to be conducted in an orderly manner within the legal and regulatory framework [1] - The announcement reflects the company's confidence in its long-term growth prospects and prudent consideration of shareholder interests [1] Group 2: Business Performance - In 2026, Fosun's core sectors, including biomedicine, cultural tourism, and insurance, have shown strong momentum [2] - The biopharmaceutical sector has made significant strides, with agreements in Japan potentially exceeding USD 300 million and a global exclusive licensing agreement with Pfizer worth over USD 2 billion [2] - The cultural tourism sector has seen impressive performance, with Shanghai Yuyuan receiving nearly 1.2 million visitors during the Spring Festival, a year-on-year increase of over 20% [2] Group 3: Insurance Sector Growth - Fosun's insurance companies reported substantial growth in 2025, with Fosun United Health Insurance achieving revenue of CNY 7.84 billion, a 50% increase year-on-year [3] - Fosun's life insurance segment recorded revenue of CNY 12.598 billion, a 36.17% increase, and a net profit of CNY 647 million, up over 450% year-on-year [3] - The robust growth in core businesses is seen as a catalyst for the buyback initiative [3] Group 4: Previous Buyback Activity - Prior to the announcement, Fosun International repurchased 13.027 million shares for HKD 48.2354 million on February 27 [3] - Since January 1, 2022, the company has repurchased a total of 258.859 million shares, representing approximately 3.17% of the total issued shares, with a total expenditure of about HKD 1.19 billion [3] Group 5: Valuation Perspective - The announcement emphasizes that the buyback aligns with the overall interests of the company and its shareholders at the current valuation level [4]

Core Viewpoint - Fosun International (00656.HK) announced a share buyback plan with a total amount not exceeding HKD 1 billion, citing that the current stock price does not reflect the company's long-term value and expressing confidence in its future development [1] Group 1: Business Performance - In 2026, Fosun's core sectors, including biomedicine, cultural tourism, and insurance, continue to show strong momentum [2] - The biopharmaceutical sector has made significant strides, with a partnership with Eisai Co., Ltd. for H drug Hansai in Japan, potentially worth over USD 300 million, and a global exclusive licensing agreement with Pfizer valued at over USD 2 billion [2] - In cultural tourism, Fosun's various product lines have performed well, with Shanghai Yuyuan receiving nearly 1.2 million visitors during the Spring Festival, a year-on-year increase of over 20%, and Atlantis Sanya achieving a record revenue of RMB 124 million during the holiday, up 20% year-on-year [2] Group 2: Insurance Sector Growth - Fosun's domestic insurance companies reported significant growth in 2025, with Fosun United Health Insurance achieving revenue of RMB 7.84 billion, a 50% increase, and Fosun Puhui Life Insurance reporting revenue of RMB 12.598 billion, a 36.17% increase, with net profit soaring over 450% to RMB 647 million [3] - The robust growth in core businesses is seen as a catalyst for the share buyback, with improved asset structure and clear growth logic justifying a more reasonable market valuation [3] Group 3: Share Buyback Details - Fosun International previously repurchased 13.027 million shares for HKD 48.2354 million on February 27, and has cumulatively repurchased 258.859 million shares since January 1, 2022, accounting for 3.17% of total issued shares, with a total expenditure of approximately HKD 1.19 billion [3] - The announcement emphasized that the buyback aligns with the overall interests of the company and its shareholders at the current valuation level [4]